StonvexLoading…
StonvexStonvexStonvexCore line items from JCI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-09-30 | Annual 2024 2024-09-30 | Annual 2023 2023-09-30 | Annual 2022 2022-09-30 |
|---|---|---|---|---|
Revenue | $23.60B | $22.95B | $22.33B | $20.64B |
Operating Income | $1.97B | $1.52B | $1.11B | $1.11B |
Net Income | $3.29B | $1.71B | $1.85B | $1.53B |
EPS (Diluted) | $5.03 | $2.52 | $2.69 | $2.19 |
Total Assets | $37.94B | $42.70B | $42.24B | $42.16B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $379.00M | $606.00M | $828.00M | $2.03B |
Free Cash Flow OCF − CapEx | $2.12B | $1.07B | $1.41B | $750.00M |
Shares Outstanding | 654.10M | 676.00M | 687.40M | 699.60M |